Cargando…

Third-line treatment options in metastatic pancreatic cancer patients: a real-world study

BACKGROUND: There are currently no standard therapy regimens for the third-line treatment of metastatic pancreatic cancer (mPC) patients. The aim of the present study was to compare the efficacy and safety of different third-line therapy regimens for mPC in the real-world. METHODS: This study retros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Hong-Rui, Zhu, Peng-Fei, Deng, Ya-Ya, Chen, Zhe-Ling, Yang, Liu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552515/ https://www.ncbi.nlm.nih.gov/pubmed/37810973 http://dx.doi.org/10.3389/fonc.2023.1251258

Ejemplares similares

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
por: Shao, Yingbo, et al.
Publicado: (2022)

Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis
por: Xue, Wen-Hui, et al.
Publicado: (2023)

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study
por: Su, Yung-Yeh, et al.
Publicado: (2022)

Third-line treatment patterns and clinical outcomes for metastatic colorectal cancer: a retrospective real-world study
por: Deng, Ting, et al.
Publicado: (2023)

A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer
por: Jin, Ying, et al.
Publicado: (2022)

Real-world evidence for option value in metastatic melanoma
por: Wong, William B, et al.
Publicado: (2021)

Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis
por: Gao, Loulu, et al.
Publicado: (2023)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2020)

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis
por: Rouvinov, Keren, et al.
Publicado: (2023)

The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma
por: George, Ben, et al.
Publicado: (2021)

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
por: Nikic, Predrag, et al.
Publicado: (2022)

Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
por: Elias, Rawad, et al.
Publicado: (2022)

A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma
por: Chun, Jung Won, et al.
Publicado: (2022)

A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma
por: Tang, Hui, et al.
Publicado: (2023)

Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience
por: Wu, Pei-Ying, et al.
Publicado: (2020)

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
por: Rubió-Casadevall, Jordi, et al.
Publicado: (2023)

Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the Third-Line Setting: A Bayesian Network Analysis
por: Pan, Wen-Tao, et al.
Publicado: (2020)

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
por: Cao, Jian-zhou, et al.
Publicado: (2021)

First-Line Treatment Options for PD-L1–Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
por: Peng, Ling, et al.
Publicado: (2021)

S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study
por: Shi, Yan, et al.
Publicado: (2022)

Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma
por: Black, Christopher M., et al.
Publicado: (2023)

High-Intensity Focused Ultrasound Ablation for Unresectable Primary and Metastatic Liver Cancer: Real-World Research in a Chinese Tertiary Center With 275 Cases
por: Ji, Yongshuo, et al.
Publicado: (2020)

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
por: Li, Qizheng, et al.
Publicado: (2022)

First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma – A real-world experience from Israel
por: Averbuch, Itamar, et al.
Publicado: (2023)

Corrigendum: Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma
por: Black, Christopher M., et al.
Publicado: (2023)

Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
por: Al-Farsi, Abdulaziz, et al.
Publicado: (2014)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2022)

Case report: Long-term survival in a patient with metastatic colorectal cancer treated with trifluridine/tipiracil in the third-line setting
por: ELBassiouny, Mohamed
Publicado: (2023)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)

Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data
por: Argyropulo-Palmer, Miriam, et al.
Publicado: (2015)

Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: A Real-World Study in China
por: Zhao, Lin, et al.
Publicado: (2019)

Long-lasting response to third-line chemotherapy in metastatic pancreatic cancer
por: Tavares, Alda, et al.
Publicado: (2020)

Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
por: Bukhari, Nedal, et al.
Publicado: (2021)

Case report: (18)F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2- metastatic breast cancer patient
por: Pan, Bo, et al.
Publicado: (2022)

Editorial: Real-world data and real-world evidence in hematologic malignancies
por: Malagola, Michele, et al.
Publicado: (2023)

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q53b1aeegmq0h72n02ui14g6le